|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qin H, Wang F, Liu H, Zeng Z, Wang S, Pan
X and Gao H: New advances in immunotherapy for non-small cell lung
cancer. Am J Transl Res. 10:2234–2245. 2018.PubMed/NCBI
|
|
4
|
Li Z, Song Y, Liu L, Hou N, An X, Zhan D,
Li Y, Zhou L, Li P, Yu L, et al: miR-199a impairs autophagy and
induces cardiac hypertrophy through mTOR activation. Cell Death
Differ. 24:1205–1213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mao M, Wu Z and Chen J: MicroRNA-187-5p
suppresses cancer cell progression in non-small cell lung cancer
(NSCLC) through down-regulation of CYP1B1. Biochem Biophys Res
Commun. 478:649–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I; Eurocare-4 Working
Group, : Recent cancer survival in Europe: A 2000-02 period
analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Z and Rana TM: Therapeutic targeting of
microRNAs: Current status and future challenges. Nat Rev Drug
Discov. 13:622–638. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Behm-Ansmant I, Rehwinkel J and Izaurralde
E: MicroRNAs silence gene expression by repressing protein
expression and/or by promoting mRNA decay. Cold Spring Harb Symp
Quant Biol. 71:523–530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Florczuk M, Szpechcinski A and
Chorostowska-Wynimko J: miRNAs as biomarkers and therapeutic
targets in non-small cell lung cancer: Current perspectives. Target
Oncol. 12:179–200. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu BB, Gu ZF, Ma M, Wang JY and Wang HN:
MicroRNA-590-5p suppresses the proliferation and invasion of
non-small cell lung cancer by regulating GAB1. Eur Rev Med
Pharmacol Sci. 22:5954–5963. 2018.PubMed/NCBI
|
|
12
|
Boldrini L, Giordano M, Lucchi M, Melfi F
and Fontanini G: Expression profiling and microRNA regulation of
the LKB1 pathway in young and aged lung adenocarcinoma patients.
Biomed Rep. 9:198–205. 2018.PubMed/NCBI
|
|
13
|
Pan Q, Sun L, Zheng D, Li N, Shi H, Song
J, Shao G and Xu G: MicroRNA-9 enhanced cisplatin sensitivity in
nonsmall cell lung cancer cells by regulating eukaryotic
translation initiation factor 5A2. Biomed Res Int.
2018:17690402018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qi YJ, Zha WJ and Zhang W: MicroRNA-217
alleviates development of non-small cell lung cancer by inhibiting
AKT3 via PI3K pathway. Eur Rev Med Pharmacol Sci. 22:5972–5979.
2018.PubMed/NCBI
|
|
15
|
Lu J, Zhan Y, Feng J, Luo J and Fan S:
MicroRNAs associated with therapy of non-small cell lung cancer.
Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fadejeva I, Olschewski H and Hrzenjak A:
MicroRNAs as regulators of cisplatin-resistance in non-small cell
lung carcinomas. Oncotarget. 8:115754–115773. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xu Y, He J, Wang Y, Zhu X, Pan Q, Xie Q
and Sun F: miR-889 promotes proliferation of esophageal squamous
cell carcinomas through DAB2IP. FEBS Lett. 589:1127–1135. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie H, Zhang Q, Zhou H, Zhou J, Zhang J,
Jiang Y, Wang J, Meng X, Zeng L and Jiang X: microRNA-889 is
downregulated by histone deacetylase inhibitors and confers
resistance to natural killer cytotoxicity in hepatocellular
carcinoma cells. Cytotechnology. 70:513–521. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu J, Li Q, He JT and Liu GY: Expression
of TAK1/TAB1 expression in non-small cell lung carcinoma and
adjacent normal tissues and their clinical significance. Int J Clin
Exp Pathol. 8:15801–15807. 2015.PubMed/NCBI
|
|
21
|
Zhou Q, Huang SX, Zhang F, Li SJ, Liu C,
Xi YY, Wang L, Wang X, He QQ, Sun CC and Li DJ: MicroRNAs: A novel
potential biomarker for diagnosis and therapy in patients with
non-small cell lung cancer. Cell Prolif. 50:2017. View Article : Google Scholar :
|
|
22
|
Han Y and Li H: miRNAs as biomarkers and
for the early detection of non-small cell lung cancer (NSCLC). J
Thorac Dis. 10:3119–3131. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li L, Sun Y, Feng M, Wang L and Liu J:
Clinical significance of blood-based miRNAs as biomarkers of
non-small cell lung cancer. Oncol Lett. 15:8915–8925.
2018.PubMed/NCBI
|
|
24
|
Gong H, Fang L, Li Y, Du J, Zhou B, Wang
X, Zhou H, Gao L, Wang K and Zhang J: miR873 inhibits colorectal
cancer cell proliferation by targeting TRAF5 and TAB1. Oncol Rep.
39:1090–1098. 2018.PubMed/NCBI
|
|
25
|
Neil JR and Schiemann WP: Altered TAB1:I
kappaB kinase interaction promotes transforming growth factor
beta-mediated nuclear factor-kappaB activation during breast cancer
progression. Cancer Res. 68:1462–1470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shuang T, Wang M, Zhou Y, Shi C and Wang
D: NF-kappaB1, c-Rel, and ELK1 inhibit miR-134 expression leading
to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.
Oncotarget. 8:24853–24868. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Isono T, Kim CJ, Ando Y, Sakurai H, Okada
Y and Inoue H: Suppression of cell invasiveness by periostin via
TAB1/TAK1. Int J Oncol. 35:425–432. 2009.PubMed/NCBI
|
